Observational studyNeurology2019
Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.
Observational study in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06629155 (Disentangling Cognitive Functioning and Visual Scanning Deficits in Cognitive Test Results in Multiple Sclerosis), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Disentangling Cognitive Functioning and Visual Scanning Deficits in Cognitive Test Results in Multiple Sclerosis (MS)
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Training effects in oculography in multiple sclerosis patients: a one-year longitudinal study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Autoimmune Diseases and the Vestibular and Oculomotor System: Clinical Presentation, Diagnosis, and Treatment.Journal of eye movement research · 2026Review
- Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disorders.Journal of neurology · 2026Article
- What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.Journal of neurology · 2026Article
- Eye tracking as a digital biomarker in neurodegenerative diseases.Journal of neurology · 2026Review
- Isolated Paramedian Pontine Reticular Formation (PPRF) syndrome in AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report.BMC neurology · 2026Article
- A review of multiple sclerosis: From pathophysiology to latest therapeutic advances.AIMS neuroscience · 2025Review
- Augmenting early stroke diagnosis with an eye-tracker.Frontiers in neurology · 2025Article
- Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE).BMJ open · 2024Article
- Visuo-Cognitive Phenotypes in Early Multiple Sclerosis: A Multisystem Model of Visual Processing.Journal of clinical medicine · 2024Article
- A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage.Brain : a journal of neurology · 2023Article
- Unilateral Internuclear Ophthalmoplegia Following Minor Head Injury.Korean journal of neurotrauma · 2022Article
- Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics.Journal of neurology, neurosurgery, and psychiatry · 2022Article
- A model for interrogating the clinico-radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia.European journal of neurology · 2021Article
- High-resolution, ultrafast, wide-field retinal eye-tracking for enhanced quantification of fixational and saccadic motion.Biomedical optics express · 2020Article
- Eye Movement Evaluation in Multiple Sclerosis and Parkinson's Disease Using a Standardized Oculomotor and Neuro-Ophthalmic Disorder Assessment (SONDA).Frontiers in neurology · 2020Article
- [Enhancing monitoring of disease progression-remote sensoring in multiple sclerosis].Der Nervenarzt · 2019Review
- Movement Disorder in Demyelinating Disease: Tracing the Charcot's Foot Print.Annals of Indian Academy of NeurologyArticle
- Ocular-motor conduction dynamics and variability in multiple sclerosis-related internuclear ophthalmoparesis: A randomized dalfampridine trial.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe present an objective and quantitative approach for diagnosing internuclear ophthalmoplegia (INO) in multiple sclerosis (MS).
methodsA validated standardized infrared oculography protocol (DEMoNS [Demonstrate Eye Movement Networks with Saccades]) was used for quantifying prosaccades in patients with MS and healthy controls (HCs). The versional dysconjugacy index (VDI) was calculated, which describes the ratio between the abducting and adducting eye. The VDI was determined for peak velocity, peak acceleration, peak velocity divided by amplitude, and area under the curve (AUC) of the saccadic trajectory. We calculated the diagnostic accuracy for the several VDI parameters by a receiver operating characteristic analysis comparing HCs and patients with MS. The National Eye Institute Visual Function Questionnaire-25 was used to investigate vision-related quality of life of MS patients with INO.
resultsTwo hundred ten patients with MS and 58 HCs were included. The highest diagnostic accuracy was achieved by the VDI AUC of 15° horizontal prosaccades. Based on a combined VDI AUC and peak velocity divided by amplitude detection, the prevalence of an INO in MS calculated to 34%. In the INO group, 35.2% of the patients with MS reported any complaints of double vision, compared to 18.4% in the non-INO group (
conclusionsThis study provides an accurate quantitative and clinically relevant definition of an INO in MS. This infrared oculography-based INO standard will require prospective validation. The high prevalence of INO in MS provides an anatomically well described and accurately quantifiable model for treatment trials in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.